Table 3.
Stage-specificity of a single 8 mg·kg−1 dose HSA, praziquantel or artesunate was administered to mice infected with S. mansoni.
| Treatment Stage of Post-Infection | Treatment (Dose mg/kg) | Mean Number of Worms (SD) | Worm Burden Reduction (%) | ||
|---|---|---|---|---|---|
| Total | Females | Total | Females | ||
| 1–5 days | - | 38.3 (16.6) | 14.1 (7.8) | — | — |
| HSA (8) | 4.4 (2.7) *** | 1.0 (1.5) ** | 88.6 | 92.9 | |
| praziquantel (300) | 5.3 (5.4) *** | 2.3 (2.6) ** | 86.2 | 83.8 | |
| artesunate (300) | 13.6 (4.7) ** | 5.0 (1.8) * | 64.4 | 64.6 | |
| 7–11 days | HSA (8) | 7.4 (3.1) ** | 2.1 (1.5) ** | 80.7 | 85.0 |
| praziquantel (300) | 13.2 (6.3) ** | 2.5 (1.5) ** | 65.6 | 82.3 | |
| artesunate (300) | 23.8 (11.2) | 6.5 (3.6) * | 37.7 | 54.0 | |
| 21–25 days | HSA (8) | 12.1 (7.0) ** | 4.3 (3.3) * | 68.3 | 70.0 |
| praziquantel (300) | 16.7 (10.3) * | 5.0 (3.7) * | 56.4 | 64.6 | |
| artesunate (300) | 1.5 (1.3) *** | 0.2 (0.4) ** | 96.1 | 98.8 | |
| 42–46 days | HSA (8) | 9.5 (4.4) ** | 2.3 (1.4) ** | 75.2 | 84.1 |
| praziquantel (300) | 13.2 (8.5) * | 4.5 (3.5) ** | 65.6 | 68.1 | |
| artesunate (300) | 2.5 (2.5) *** | 0.7 (0.7) ** | 93.5 | 95.3 | |
| 49–53 days | HSA (8) | 11.3 (4.1) ** | 2.5 (1.4) ** | 70.6 | 82.3 |
| praziquantel (300) | 1.3 (0.7) ** | 0.3 (0.5) *** | 96.5 | 97.6 | |
| artesunate (300) | 13.7(7.0) ** | 3.8 (2.0) ** | 64.3 | 72.9 | |
* p < 0.05, ** p < 0.01 *** p < 0.001 vs. the Negative control group, t-test.